 | • レポートコード：MRC2302E0170 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、251ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医療 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本調査レポートは、2021年に240.88百万ドルであった世界の幹細胞療法市場規模が、2022年に286.61百万ドルになり、2027年まで年平均19.16%で成長して689.69百万ドルに達すると予測しています。本レポートでは、幹細胞療法の世界市場について調査し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、細胞源別（脂肪組織由来MSC、骨髄由来MSC、胎盤＆へその緒由来MSC）分析、種類別（同種幹細胞療法、自家幹細胞療法）分析、治療用途別（心臓血管疾患手術、炎症性疾患＆自己免疫疾患、筋骨格疾患、神経障害、傷＆怪我）分析、エンドユーザー別（学術＆研究機関、外来手術センター、病院＆診療所）分析、地域別（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）分析、競争状況、企業情報などの項目を掲載しています。また、本書には、Advanced Cell Technology, Inc.、AlloSource, Inc.、Anterogen Co., Ltd.、Bioheart Inc.、BioTime, Inc.、BrainStorm Cell Therapeutics Inc.、Celgene Corporation、Cellartis AB、CellGenix GmbH、Cellular Engineering Technologies Inc.、Gamida Cell Ltd、Gilead Sciences, Inc.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の幹細胞療法市場規模：細胞源別 - 脂肪組織由来MSCの市場規模 - 骨髄由来MSCの市場規模 - 胎盤＆へその緒由来MSCの市場規模 ・世界の幹細胞療法市場規模：種類別 - 同種幹細胞療法の市場規模 - 自家幹細胞療法の市場規模 ・世界の幹細胞療法市場規模：治療用途別 - 心臓血管疾患手術における市場規模 - 炎症性疾患＆自己免疫疾患における市場規模 - 筋骨格疾患における市場規模 - 神経障害における市場規模 - 傷＆怪我における市場規模 ・世界の幹細胞療法市場規模：エンドユーザー別 - 学術＆研究機関における市場規模 - 外来手術センターにおける市場規模 - 病院＆診療所における市場規模 ・世界の幹細胞療法市場規模：地域別 - 南北アメリカの幹細胞療法市場規模 アメリカの幹細胞療法市場規模 カナダの幹細胞療法市場規模 ブラジルの幹細胞療法市場規模 ... - アジア太平洋の幹細胞療法市場規模 日本の幹細胞療法市場規模 中国の幹細胞療法市場規模 インドの幹細胞療法市場規模 韓国の幹細胞療法市場規模 台湾の幹細胞療法市場規模 ... -ヨーロッパ/中東/アフリカの幹細胞療法市場規模 イギリスの幹細胞療法市場規模 ドイツの幹細胞療法市場規模 フランスの幹細胞療法市場規模 ロシアの幹細胞療法市場規模 ... -その他地域の幹細胞療法市場規模 ・競争状況 ・企業情報 |
The Global Stem Cell Therapy Market size was estimated at USD 240.88 million in 2021 and expected to reach USD 286.61 million in 2022, and is projected to grow at a CAGR 19.16% to reach USD 689.69 million by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Stem Cell Therapy to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Cell Source, the market was studied across Adipose tissue-derived MSCs (mesenchymal stem cells),, Bone marrow-derived MSCs,, and Placental/umbilical cord-derived MSCs.
Based on Type, the market was studied across Allogeneic Stem Cell Therapy and Autologous Stem Cell Therapy.
Based on Therapeutic Application, the market was studied across Cardiovascular Diseases Surgeries, Inflammatory & Autoimmune Diseases, Musculoskeletal Disorders, Neurological Disorders, Other Therapeutic Applications, and Wounds & Injuries.
Based on End-User, the market was studied across Academic and Research Centers, Ambulatory Surgical Centers (ASCs), and Hospitals & Clinics.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Stem Cell Therapy market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Stem Cell Therapy Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Stem Cell Therapy Market, including Advanced Cell Technology, Inc., AlloSource, Inc., Anterogen Co., Ltd., Bioheart Inc., BioTime, Inc., BrainStorm Cell Therapeutics Inc., Celgene Corporation, Cellartis AB, CellGenix GmbH, Cellular Engineering Technologies Inc., Gamida Cell Ltd, Gilead Sciences, Inc., Holostem Terapie Avanzate Srl, JCR Pharmaceuticals Co., Ltd., Lonza Group AG, Medipost Co., Ltd., Nuvasive, Inc., Osiris Therapeutics, Inc., Pharmicell Co., Ltd., Pluristem Therapeutics Inc., PromoCell GmbH, RTI Surgical, Inc., STEMCELL Technologies, Inc., Takeda Pharmaceutical Company Limited, Vericel Corporation, and VistaGen Therapeutics, Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Stem Cell Therapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Stem Cell Therapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Stem Cell Therapy Market?
4. What is the competitive strategic window for opportunities in the Global Stem Cell Therapy Market?
5. What are the technology trends and regulatory frameworks in the Global Stem Cell Therapy Market?
6. What is the market share of the leading vendors in the Global Stem Cell Therapy Market?
7. What modes and strategic moves are considered suitable for entering the Global Stem Cell Therapy Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising demand for therapeutic potency of stem cells in disease management
5.1.1.2. Increasing government initiatives for stem cell therapy across the world
5.1.1.3. Extensive growth in the prevalence of chronic diseases
5.1.2. Restraints
5.1.2.1. Relatively high cost of the therapy
5.1.3. Opportunities
5.1.3.1. Ongoing advancements in regenerative medicine
5.1.3.2. Rising research and development activities in stem cell therapy
5.1.4. Challenges
5.1.4.1. Concerns over ethical issues with stem cell therapy
5.2. Cumulative Impact of COVID-19
6. Stem Cell Therapy Market, by Cell Source
6.1. Introduction
6.2. Adipose tissue-derived MSCs (mesenchymal stem cells),
6.3. Bone marrow-derived MSCs,
6.4. Placental/umbilical cord-derived MSCs
7. Stem Cell Therapy Market, by Type
7.1. Introduction
7.2. Allogeneic Stem Cell Therapy
7.3. Autologous Stem Cell Therapy
8. Stem Cell Therapy Market, by Therapeutic Application
8.1. Introduction
8.2. Cardiovascular Diseases Surgeries
8.3. Inflammatory & Autoimmune Diseases
8.4. Musculoskeletal Disorders
8.5. Neurological Disorders
8.6. Other Therapeutic Applications
8.7. Wounds & Injuries
9. Stem Cell Therapy Market, by End-User
9.1. Introduction
9.2. Academic and Research Centers
9.3. Ambulatory Surgical Centers (ASCs)
9.4. Hospitals & Clinics
10. Americas Stem Cell Therapy Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States
11. Asia-Pacific Stem Cell Therapy Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam
12. Europe, Middle East & Africa Stem Cell Therapy Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom
13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.1.1. Quadrants
13.1.2. Business Strategy
13.1.3. Product Satisfaction
13.2. Market Ranking Analysis, By Key Player
13.3. Market Share Analysis, By Key Player
13.4. Competitive Scenario
13.4.1. Merger & Acquisition
13.4.2. Agreement, Collaboration, & Partnership
13.4.3. New Product Launch & Enhancement
13.4.4. Investment & Funding
13.4.5. Award, Recognition, & Expansion
14. Company Usability Profiles
14.1. Advanced Cell Technology, Inc.
14.1.1. Business Overview
14.1.2. Key Executives
14.1.3. Product & Services
14.2. AlloSource, Inc.
14.2.1. Business Overview
14.2.2. Key Executives
14.2.3. Product & Services
14.3. Anterogen Co., Ltd.
14.3.1. Business Overview
14.3.2. Key Executives
14.3.3. Product & Services
14.4. Bioheart Inc.
14.4.1. Business Overview
14.4.2. Key Executives
14.4.3. Product & Services
14.5. BioTime, Inc.
14.5.1. Business Overview
14.5.2. Key Executives
14.5.3. Product & Services
14.6. BrainStorm Cell Therapeutics Inc.
14.6.1. Business Overview
14.6.2. Key Executives
14.6.3. Product & Services
14.7. Celgene Corporation
14.7.1. Business Overview
14.7.2. Key Executives
14.7.3. Product & Services
14.8. Cellartis AB
14.8.1. Business Overview
14.8.2. Key Executives
14.8.3. Product & Services
14.9. CellGenix GmbH
14.9.1. Business Overview
14.9.2. Key Executives
14.9.3. Product & Services
14.10. Cellular Engineering Technologies Inc.
14.10.1. Business Overview
14.10.2. Key Executives
14.10.3. Product & Services
14.11. Gamida Cell Ltd
14.11.1. Business Overview
14.11.2. Key Executives
14.11.3. Product & Services
14.12. Gilead Sciences, Inc.
14.12.1. Business Overview
14.12.2. Key Executives
14.12.3. Product & Services
14.13. Holostem Terapie Avanzate Srl
14.13.1. Business Overview
14.13.2. Key Executives
14.13.3. Product & Services
14.14. JCR Pharmaceuticals Co., Ltd.
14.14.1. Business Overview
14.14.2. Key Executives
14.14.3. Product & Services
14.15. Lonza Group AG
14.15.1. Business Overview
14.15.2. Key Executives
14.15.3. Product & Services
14.16. Medipost Co., Ltd.
14.16.1. Business Overview
14.16.2. Key Executives
14.16.3. Product & Services
14.17. Nuvasive, Inc.
14.17.1. Business Overview
14.17.2. Key Executives
14.17.3. Product & Services
14.18. Osiris Therapeutics, Inc.
14.18.1. Business Overview
14.18.2. Key Executives
14.18.3. Product & Services
14.19. Pharmicell Co., Ltd.
14.19.1. Business Overview
14.19.2. Key Executives
14.19.3. Product & Services
14.20. Pluristem Therapeutics Inc.
14.20.1. Business Overview
14.20.2. Key Executives
14.20.3. Product & Services
14.21. PromoCell GmbH
14.21.1. Business Overview
14.21.2. Key Executives
14.21.3. Product & Services
14.22. RTI Surgical, Inc.
14.22.1. Business Overview
14.22.2. Key Executives
14.22.3. Product & Services
14.23. STEMCELL Technologies, Inc.
14.23.1. Business Overview
14.23.2. Key Executives
14.23.3. Product & Services
14.24. Takeda Pharmaceutical Company Limited
14.24.1. Business Overview
14.24.2. Key Executives
14.24.3. Product & Services
14.25. Vericel Corporation
14.25.1. Business Overview
14.25.2. Key Executives
14.25.3. Product & Services
14.26. VistaGen Therapeutics, Inc.
14.26.1. Business Overview
14.26.2. Key Executives
14.26.3. Product & Services
15. Appendix
15.1. Discussion Guide
15.2. License & Pricing